Clinical Trial Detail

NCT ID	NCT04471415
Title	First-in-human Study of DRP-104 as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors.
Recruitment	Recruiting
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	Dracen Pharmaceuticals, Inc.
Indications	lung non-small cell carcinoma hypopharynx cancer head and neck squamous cell carcinoma oral cavity cancer Advanced Solid Tumor laryngeal squamous cell carcinoma oropharynx cancer
Therapies	DRP-104 Atezolizumab + DRP-104
Age Groups:	adult senior